T4	control 88 95	placebo
T5	condition 99 134	haemostasis and cardiovascular risk
T8	eligibility 637 658	post-menopausal women
T9	control-participants 724 726	55
T10	intervention-participants 765 767	56
T11	intervention-participants 854 856	56
T12	control-participants 812 814	59
T14	outcome 1066 1083	fibrinogen levels
T15	iv-cont-median 1120 1125	-5.7%
T16	iv-cont-median 1139 1144	-1.1%
T17	outcome 1166 1183	Total cholesterol
T18	outcome 1220 1225	HDL-C
T19	outcome 1355 1368	Triglycerides
T20	outcome 1519 1535	Antithrombin-III
T22	iv-cont-median 1427 1432	21.4%
T23	iv-cont-median 1470 1474	8.6%
T1	intervention 14 80	transdermal estradiol or oral conjugated oestrogen and fenretinide
